GENFIT : FDA has officially cleared the IND to proceed

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
GENFIT : FDA has officially cleared the IND to proceed with Phase II trial and evaluate elafibranor in PBC

GENFIT: FDA has officially cleared the IND to proceed with Phase II trial and evaluate elafibranor in PBC

  • Investigational New Drug (IND) application cleared by the FDA for the new indication of elafibranor in Primary Biliary Cholangitis (PBC), a rare disease with unmet need and only two orphan products approved to date

Lille (France), Cambridge (Massachusetts, United States), November 4, 2016 - GENFIT (Euronext: GNFT - ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announced that the FDA has cleared the IND to proceed with the Phase II trial aimed at evaluating elafibranor in PBC.

As previously announced, this trial is designed to be a multicenter, double-blind, randomized, placebo-controlled, Phase II study to evaluate the efficacy and safety of elafibranor after 12 weeks of treatment in patients with PBC and inadequate response to ursodeoxycholic acid.

The primary objective is to determine the effect of daily oral administration of elafibranor on serum alkaline phosphatase (ALP) in these patients, based on relative change versus placebo.

Secondary endpoints will include:

  • ALP < 1.67 × upper limit of normal (ULN) and total bilirubin within normal limit and > 15% decrease in ALP
  • Paris, Toronto, UK PBC scores
  • Pruritus and QoL (Quality of Life)
  • Safety of elafibranor in a PBC population

PBC is a rare disease with unmet need. Current treatments only cure a fraction of the patient population, and/or generate important side effects such as pruritus, which is a major and well-known symptom already affecting most PBC patients.

Jean-François Mouney, CEO, Co-founder, and Chairman of the board of GENFIT commented: " We are satisfied with the progress made on the regulatory side in PBC. Our presence in this field is highly relevant given the profile of elafibranor, our proprietary molecule. We soon hope to be able to provide patients with a new, safe and well-tolerated therapeutic solution. Our involvement in PBC will continue to enrich our medical network thanks to our broad discussions and interactions we have with hepatologists. We value and cultivate a high level of collaboration with the medical community as it's a way for us to ensure that the best decisions are made to address unmet medical needs in this field. "

About elafibranor:

Elafibranor is GENFIT's lead pipeline product. Elafibranor is an oral once-daily treatment, and a first-in-class drug acting via dual peroxisome proliferator-activated alpha/delta pathways developed to treat, in particular, nonalcoholic steatohepatitis (NASH). Elafibranor is believed to address multiple facets of NASH, including inflammation, insulin sensitivity, lipid/metabolic profile, and liver markers. The drug will also be evaluated in Primary Biliary Cholangitis (PBC).

About PBC:

"PBC" or Primary Biliary Cholangitis, is a chronic disease in which bile ducts in the liver are gradually destroyed. The damage to bile ducts can inhibit the liver's ability to rid the body of toxins, and can lead to scarring of liver tissue known as cirrhosis.

About GENFIT:

GENFIT is a biopharmaceutical company focused on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatment and an increasing number of patients worldwide. GENFIT's R&D efforts are focused on bringing new medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as NASH - Nonalcoholic steatohepatitis) and more generally the gastro-intestinal arena. GENFIT's approach combines novel treatments and biomarkers. Its lead proprietary compound, elafibranor, is currently in a Phase 3 study. With facilities in Lille and Paris, France, and Cambridge, MA (USA), the Company has approximately 110 employees. GENFIT is a public company listed in compartment B of Euronext's regulated market in Paris (Euronext: GNFT - ISIN: FR0004163111). www.genfit.com

Forward Looking Statement / Disclaimer:

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, including related to biomarkers, progression of, and results of clinical data from, the RESOLVE-IT trial, review and approvals by regulatory authorities, such as the FDA or the EMA, regarding in particular, elafibranor in NASH and PBC, as well as other indications, and biomarkers, the success of any inlicensing strategies, the Company's continued ability to raise capital to fund its development, as well as those discussed or identified in the Company's public filings with the AMF, including those listed under Section 7 "Main Risks and Uncertainties"of the Company's Half Year 2016 Business and Financial Report, which is available on GENFIT's website (www.genfit.com) and on the website of the AMF (www.amf-france.org). Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in GENFIT in any country. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.

CONTACT

GENFIT | Jean-François Mouney - Chairman & CEO | Ph. +333 2016 4000 MILESTONES - Press Relations | Bruno Arabian | Ph. +331 8362 3484 / +336 8788 4726 - barabian@milestones.fr

Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...8cd258d201

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Visit W&H at the Greater New York Dental Meeting

Updated Category News Views 89

Why This Event Matters for Dental Professionals Stroll through any convention center halls and you can see the future unfolding right in front of you. The upcoming Greater New York Dental Meeting is no different, especially with W&H Group setting up shop. For any dental professionals out there, this is your chance to get your hands on some real-deal tech that might just...

Continue Reading
Lennar Faces Securities Fraud Lawsuit: Investor Insights

Updated Category News Views 168

Investors in Lennar: Navigating the Legal Storm Hold onto your hats, folks. Lennar Corporation (NYSE: LEN) is up against it with a brand-spanking-new securities fraud lawsuit helmed by Schall, Brown & Schwartz LLP (SBS). This isn't just a couple of investors grumbling over cocktails; it’s a full-blown class action that’s waving the legal banner under the Securities...

Continue Reading
Silvi's Expansion Push: New Terminal in Wilmington

Updated Category News Views 113

Silvi's Latest Bet on the Southeast You know, sometimes you get a gut feeling that a company is rolling out chess moves instead of checkers. That’s what Silvi Materials is up to with their new project in Wilmington. It’s not just some fancy cement terminal—it’s a calculated expansion into the heart of the Southeast construction market. The Port of Wilmington’s...

Continue Reading
SiteOne Joins S&P SmallCap 600 Amid KKR's Integer Buyout

Updated Category News Views 99

Changes on the SmallCap Horizon Starting off, SiteOne Landscape Supply (NYSE: SITE) is hopping onto the S&P SmallCap 600 bandwagon. This shift activates just as the market revs up on November 19, 2026. SiteOne is stepping in as Integer Holdings Corp. (NYSE: ITGR) makes its grand exit, a move prompted by a significant acquisition by KKR & Co. Inc. (NYSE: KKR). KKR’s...

Continue Reading
Terminus Ballet: A Decade of Defying Dance Norms

Updated Category News Views 183

A Dance Company's Journey of Transformation An anniversary represents more than just a celebration; it's a reminder of the road traveled. On Jan. 30, 2027, Terminus Modern Ballet Theatre will mark its 10th anniversary, encapsulating a decade of defiance against the staid conventions binding classical ballet. This isn't just about pirouettes and pliés—it's dance with a...

Continue Reading
Cheyenne Real Estate: Neighborhood Nuances and Choices

Updated Category News Views 149

Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...

Continue Reading
Halfday Iced Tea Shakes Up U.S. Retail Scene

Updated Category News Views 150

Halfday's Meteoric Rise in the U.S. Market Sometimes, you pick up a can of iced tea, and it just changes the game. That’s exactly what Halfday is doing, stepping on the accelerator and leaving traditional iced tea brands in the dust. With their latest announcement, they've snagged the title of the fastest-growing modern tea brand in U.S. multi-outlet retail. It's the...

Continue Reading
Chicago Auto Show: Run & Explore Indoors This February

Updated Category News Views 136

Nobody’s thinking about running laps when they walk into a colossal auto show, but the Chicago Auto Show isn't letting the pedal ease off the gas. Swing by on February 14, folks, for something not typically seen on the floors of McCormick Place. Run participants have got one hour to log as many miles as they can on the 2.4-mile loop right inside the show. Why a Running...

Continue Reading
Insight Into Midland TX Real Estate Sales Timing

Updated Category News Views 46

How Fast Do Homes Move in Midland? This ain't my first rodeo predicting the real estate rollercoaster in Texas. Midland's housing market is one nifty beast—homes can either sell like hotcakes or just sit gathering dust. You got HelloNation pulling in DeLaura Gammage, a pro who knows the terrain like the back of her hand, to spell out the why and how long it'll take to...

Continue Reading
Loyalty Programs Cut $1500 Annually for Consumers

Updated Category News Views 122

Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...

Continue Reading

Top 5 Most Recently Viewed Articles

Chuyuan Group's Transformative Journey Towards Sustainable Success

Updated Category News Views 226

Chuyuan Group's Path to Sustainability and Growth In recent years, Chuyuan Group has significantly transformed its operations, embracing high-quality development in response to the evolving regulatory landscape. As the industry landscape changes, companies like Chuyuan must adapt to remain competitive and environmentally responsible. Understanding the Shift: Old Yang and...

Continue Reading
Adani Bonds Face Downgrade Risk Amid U.S. Bribery Scandal

Updated Category News Views 355

Fitch Ratings Puts Adani Group Bonds on Negative Watch In a significant move, Fitch Ratings has placed bonds from various units of the Adani Group on a watchlist for potential downgrades. This action follows serious allegations against the conglomerate's top executives, who are facing U.S. charges related to bribery and fraud. Implications of the Watch Status Fitch's...

Continue Reading
Investigation of Arbor Realty Trust: What Investors Should Know

Updated Category News Views 81

Understanding the Investigation of Arbor Realty Trust Faruqi & Faruqi, LLP, a well-known national securities law firm, is currently looking into claims related to Arbor Realty Trust, Inc. (NYSE: ABR). Investors who have suffered losses exceeding $100,000 while investing in Arbor are encouraged to get in touch for more information and support. Who Should Reach Out to...

Continue Reading
Qualcomm's Strategic Move: Potential Intel Acquisition Talks

Updated Category News Views 185

Qualcomm's Interest in Intel's Assets Recently, Qualcomm has made headlines by showing interest in buying parts of Intel. This move seems to be a strategic effort by Qualcomm to strengthen its presence in the competitive technology market, especially within the chip manufacturing sector. Shifting Market Dynamics Intel, a leader in chip production, is currently facing...

Continue Reading
Refined Energy Corp Expands Partnership with Eagle Plains Resources

Updated Category News Views 113

Refined Energy Corp Strengthens Its Partnership Refined Energy Corp announces an important amendment to its agreement with Eagle Plains Resources Ltd. The key focus of this amendment is to enhance their collaboration on the Dufferin Project, a project located in Canada's Athabasca Basin, known for its rich mineral deposits. Details of the Amended Agreement In a recent...

Continue Reading